A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma (vol 27, pg 2212, 2021)

被引：2

作者：

Kjeldsen, Julie Westerlin

Lorentzen, Cathrine Lund

Martinenaite, Evelina

Ellebaek, Eva

Donia, Marco

Holmstroem, Rikke Boedker

Klausen, Tobias Wirenfeldt

Madsen, Cecilie Oelvang

Ahmed, Shamaila Munir

Weis-Banke, Stine Emilie

Holmstrom, Morten Orebo

Hendel, Helle Westergren

Ehrnrooth, Eva

Zocca, Mai-Britt

Pedersen, Ayako Wakatsuki

Andersen, Mads Hald

Svane, Inge Marie

机构：

[1] Copenhagen University Hospital,National Center for Cancer Immune Therapy (CCIT

[2] IO Biotech Aps,DK), Department of Oncology

[3] Copenhagen University Hospital,Department of Clinical Physiology and Nuclear Medicine

[4] University of Copenhagen,Department of Immunology and Microbiology

来源：

NATURE MEDICINE | 2022年 / 28卷 / 04期

关键词：

D O I：

10.1038/s41591-022-01771-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：871 / 871

页数：1

共 50 条

[1] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Kjeldsen, Julie Westerlin
Lorentzen, Cathrine Lund
Martinenaite, Evelina
Ellebaek, Eva
Donia, Marco
Holmstroem, Rikke Boedker
Klausen, Tobias Wirenfeldt
Madsen, Cecilie Oelvang
Ahmed, Shamaila Munir
Weis-Banke, Stine Emilie
Holmstrom, Morten Orebo
Hendel, Helle Westergren
Ehrnrooth, Eva
Zocca, Mai-Britt
Pedersen, Ayako Wakatsuki
Andersen, Mads Hald
Svane, Inge Marie
[J]. NATURE MEDICINE, 2021, 27 (12) : 2212 - +
[2] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen
Cathrine Lund Lorentzen
Evelina Martinenaite
Eva Ellebaek
Marco Donia
Rikke Boedker Holmstroem
Tobias Wirenfeldt Klausen
Cecilie Oelvang Madsen
Shamaila Munir Ahmed
Stine Emilie Weis-Banke
Morten Orebo Holmström
Helle Westergren Hendel
Eva Ehrnrooth
Mai-Britt Zocca
Ayako Wakatsuki Pedersen
Mads Hald Andersen
Inge Marie Svane
[J]. Nature Medicine, 2021, 27 : 2212 - 2223
[3] Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen
Cathrine Lund Lorentzen
Evelina Martinenaite
Eva Ellebaek
Marco Donia
Rikke Boedker Holmstroem
Tobias Wirenfeldt Klausen
Cecilie Oelvang Madsen
Shamaila Munir Ahmed
Stine Emilie Weis-Banke
Morten Orebo Holmström
Helle Westergren Hendel
Eva Ehrnrooth
Mai-Britt Zocca
Ayako Wakatsuki Pedersen
Mads Hald Andersen
Inge Marie Svane
[J]. Nature Medicine, 2022, 28 : 871 - 871
[4] Combination therapy with nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. A clinical trial in progress
Kjeldsen, J. W.
Andersen, M. H.
Svane, I-M.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[5] Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
Svane, I-M.
Kjeldsen, J. W.
Lorentzen, C. L.
Martinenaite, E.
Andersen, M. H.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1176 - S1176
[6] High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab
Kjeldsen, Julie W.
Lorentzen, Cathrine L.
Martinenaite, Evelina
Ellebaek, Eva
Donia, Marco
Ehrnrooth, Eva
Andersen, Mads H.
Svane, Inge Marie
[J]. CANCER RESEARCH, 2022, 82 (12)
[7] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
VanderWalde, Ari
Bellasea, Shay L.
Kendra, Kari L.
Khushalani, Nikhil I.
Campbell, Katie M.
Scumpia, Philip O.
Kuklinski, Lawrence F.
Collichio, Frances
Sosman, Jeffrey A.
Ikeguchi, Alexandra
Victor, Adrienne I.
Truong, Thach-Giao
Chmielowski, Bartosz
Portnoy, David C.
Chen, Yuanbin
Margolin, Kim
Bane, Charles
Dasanu, Constantin A.
Johnson, Douglas B.
Eroglu, Zeynep
Chandra, Sunandana
Medina, Egmidio
Gonzalez, Cynthia R.
Baselga-Carretero, Ignacio
Vega-Crespo, Agustin
Garcilazo, Ivan Perez
Sharon, Elad
Hu-Lieskovan, Siwen
Patel, Sapna P.
Grossmann, Kenneth F.
Moon, James
Wu, Michael C.
Ribas, Antoni
[J]. NATURE MEDICINE, 2023, 29 (09) : 2278 - +
[8] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Ari VanderWalde
Shay L. Bellasea
Kari L. Kendra
Nikhil I. Khushalani
Katie M. Campbell
Philip O. Scumpia
Lawrence F. Kuklinski
Frances Collichio
Jeffrey A. Sosman
Alexandra Ikeguchi
Adrienne I. Victor
Thach-Giao Truong
Bartosz Chmielowski
David C. Portnoy
Yuanbin Chen
Kim Margolin
Charles Bane
Constantin A. Dasanu
Douglas B. Johnson
Zeynep Eroglu
Sunandana Chandra
Egmidio Medina
Cynthia R. Gonzalez
Ignacio Baselga-Carretero
Agustin Vega-Crespo
Ivan Perez Garcilazo
Elad Sharon
Siwen Hu-Lieskovan
Sapna P. Patel
Kenneth F. Grossmann
James Moon
Michael C. Wu
Antoni Ribas
[J]. Nature Medicine, 2023, 29 : 2278 - 2285
[9] Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Lorentzen, Cathrine Lund
Kjeldsen, Julie Westerlin
Ehrnrooth, Eva
Andersen, Mads Hald
Svane, Inge Marie
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (05)
[10] Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
Jorgensen, Nicolai Gronne
Klausen, Uffe
Grauslund, Jacob Handlos
Helleberg, Carsten
Aagaard, Thomas Granum
Do, Trung Hieu
Ahmad, Shamaila Munir
Olsen, Lars Ronn
Klausen, Tobias Wirenfeldt
Breinholt, Marie Fredslund
Hansen, Morten
Martinenaite, Evelina
Met, Ozcan
Svane, Inge Marie
Knudsen, Lene Meldgaard
Andersen, Mads Hald
[J]. FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 →